Want to see COGT full AI Analyst Report?
COGT Stock Chart & Stats
$39.76
-$0.48(-1.19%)
At close: 4:00 PM EDT
$39.76
-$0.48(-1.19%)
Day’s Range― - ―
52-Week Range$10.38 - $43.73
Previous CloseN/A
Volume1.59M
Average Volume (3M)2.84M
Market Cap
$6.65B
Enterprise Value$5.68K
Total Cash (Recent Filing)$866.38M
Total Debt (Recent Filing)$238.65M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 11, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.08
Shares Outstanding170,868,010
10 Day Avg. Volume1,953,092
30 Day Avg. Volume2,837,687
Financial Highlights & Ratios
PEG Ratio-3.81
Price to Book (P/B)3.77
Price to Sales (P/S)0.00
P/FCF Ratio-9.03
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$54.00Price Target Upside35.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$11.88M
Bulls Say, Bears Say
Bulls Say
Strong Equity CushionA sizable equity base (~$608M vs ~$903M assets) gives Cogent a durable capital buffer to support multi-year clinical development. This reduces immediate insolvency risk, enables staged R&D investment and strategic options (partnerships or non-dilutive financing) versus a capital-poor peer.
Moderate LeverageReported debt-to-equity near 0.39–0.40 indicates manageable leverage for a clinical-stage biotech. That level preserves the company’s ability to access debt markets as a financing tool, providing optionality beyond equity raises and supporting funding flexibility across multi-year trials.
Focused Precision-medicine PipelineA concentrated focus on KIT-driven, genetically defined diseases is a structural advantage: biomarker-driven development can improve trial efficiency, enable targeted regulatory strategies, and attract partnership interest. Clear patient segmentation supports durable product-development clarity and go-to-market planning.
Bears Say
No Commercial RevenueAbsent product sales, Cogent’s operating model relies on external financing and partnerships rather than recurring cash flow. Over a 2–6 month horizon this structural dependence elevates execution risk: trial milestones and capital-market access will dictate continuity and resource allocation.
Widening Net LossesRapidly increasing net losses signal accelerating investment burn and deteriorating operating leverage. Persistent widening losses make sustained R&D investment expensive, increase the likelihood of dilutive financings, and heighten pressure to prioritize programs or seek partnerships to conserve cash.
Heavy, Rising Cash BurnOperating cash outflows have increased sharply to roughly -$285M TTM, with free cash flow similarly negative. This persistent and volatile burn creates an ongoing capital requirement, raising the probability of near-term raises and potential program deferral or asset monetization to preserve runway.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences, Inc.’s price range in the past 12 months?
Cogent Biosciences, Inc. lowest stock price was $10.38 and its highest was $43.73 in the past 12 months.
What is Cogent Biosciences, Inc.’s market cap?
Cogent Biosciences, Inc.’s market cap is $6.65B.
When is Cogent Biosciences, Inc.’s upcoming earnings report date?
Cogent Biosciences, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 4 days.
How were Cogent Biosciences, Inc.’s earnings last quarter?
Cogent Biosciences, Inc. released its earnings results on May 05, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.533 by $0.003.
Is Cogent Biosciences, Inc. overvalued?
According to Wall Street analysts Cogent Biosciences, Inc.’s price is currently Undervalued.
Does Cogent Biosciences, Inc. pay dividends?
Cogent Biosciences, Inc. does not currently pay dividends.
What is Cogent Biosciences, Inc.’s EPS estimate?
Cogent Biosciences, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Cogent Biosciences, Inc. have?
Cogent Biosciences, Inc. has 170,868,010 shares outstanding.
What happened to Cogent Biosciences, Inc.’s price movement after its last earnings report?
Cogent Biosciences, Inc. reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.533. Following the earnings report the stock price went up 0.681%.
Which hedge fund is a major shareholder of Cogent Biosciences, Inc.?
Currently, no hedge funds are holding shares in COGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogent Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (35.81% Upside)
$54.00 (35.81% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
218.19%
Trailing 12-Months
Company Description
Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
COGT Stock 12 Month Forecast
Average Price Target
$54.00
▲(35.81% Upside)
Technical Analysis
PTC Therapeutics
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Mirum Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Ownership Overview
4.03% Insiders
30.75% Mutual Funds
3.43% Other Institutional Investors
44.70% Public Companies and
Individual Investors